Vyome (NASDAQ:HIND – Get Free Report) and Nanovibronix (NASDAQ:FEED – Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.
Valuation & Earnings
This table compares Vyome and Nanovibronix”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vyome | $8.01 million | 1.94 | -$7.13 million | ($125.20) | -0.02 |
| Nanovibronix | $2.69 million | 1.10 | -$3.70 million | ($41.74) | -0.06 |
Profitability
This table compares Vyome and Nanovibronix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vyome | -270.58% | -423.39% | -166.02% |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Vyome and Nanovibronix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vyome | 1 | 0 | 2 | 0 | 2.33 |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
Vyome currently has a consensus target price of $15.00, suggesting a potential upside of 445.45%. Given Vyome’s stronger consensus rating and higher possible upside, analysts plainly believe Vyome is more favorable than Nanovibronix.
Institutional & Insider Ownership
22.1% of Vyome shares are held by institutional investors. Comparatively, 16.4% of Nanovibronix shares are held by institutional investors. 33.0% of Vyome shares are held by company insiders. Comparatively, 1.4% of Nanovibronix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Vyome has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500.
Summary
Vyome beats Nanovibronix on 9 of the 14 factors compared between the two stocks.
About Vyome
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Vyome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyome and related companies with MarketBeat.com's FREE daily email newsletter.
